



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2020





© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

March 2020

N = 7398



Health Authority	Male	Female	All
FRASER	1441	443	1884
INTERIOR	415	98	513
NORTHERN	135	88	223
VANCOUVER COASTAL	3342	446	3788
VANCOUVER ISLAND	801	157	958
	6134	1232	7366
		Unknown/not stated:	32
		Total:	7398

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2015 - March 2020)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2015 - March 2020)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (March 2015 - March 2020)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (March 2015 - March 2020)






1.6 Percent Distribution of Active Participants by CD4 Count (March 2015 - March 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(March 2015 - March 2020)






1.8 Active and Inactive Participants (March 2015 - March 2020)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2015 - March 2020)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (March 2015 - March 2020)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(March 2015 - March 2020)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2015 - March 2020)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(March 2015 - March 2020)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2015 - March 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(March 2015 - March 2020)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2015 - March 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(March 2015 - March 2020)






1.18 Baseline CD4 for Antiretroviral First Starts
(March 2015 - March 2020)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(March 2015 - March 2020)**






1.20 Cumulative Resistance Testing Results by Resistance Category (March 2015 - March 2020)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2015 - March 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	2	580	5	<40	3
1988	29	6	0	6	4	320	6	<40	3
1989	27	53	1	54	37	470	50	<40	3
1990	26	52	1	53	35	540	51	<40	3
1991	26	36	3	39	22	550	37	<40	3
1992	25	63	5	68	41	640	64	<40	3
1993	25	124	16	140	115	560	133	<40	3
1994	23	81	13	94	69	540	90	<40	3
1995	23	132	22	154	117	530	146	<40	3
1996	21	334	53	387	274	565	355	<40	3
1997	19	266	34	300	228	625	285	<40	3
1998	18	194	44	238	177	580	225	<40	3
1999	19	158	37	195	141	580	180	<40	3
2000	19	122	32	154	110	620	142	<40	3
2001	18	116	27	143	109	600	132	<40	3
2002	17	121	27	148	114	585	138	<40	3
2003	16	150	30	180	124	620	169	<40	3
2004	15	156	39	195	152	585	181	<40	3
2005	14	180	45	225	171	620	206	<40	3
2006	13	186	41	227	168	560	204	<40	3
2007	12	248	50	298	221	590	267	<40	3
2008	12	276	69	345	264	630	323	<40	3
2009	11	306	65	371	275	660	342	<40	3
2010	9	275	74	349	253	660	308	<40	3
2011	9	329	74	403	299	700	369	<40	3
2012	8	266	63	329	246	700	300	<40	3
2013	7	267	70	337	239	640	301	<40	3
2014	6	285	52	337	239	720	305	<40	3
2015	5	293	45	338	256	680	309	<40	3
2016	4	280	53	333	242	670	300	<40	3
2017	3	235	36	271	211	670	253	<40	3
2018	2	208	54	262	205	650	248	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	1	253	50	303	258	590	291	<40	3
2020	0	78	13	91	79	600	86	87	3
Total:		6134	1238	7372					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7397	788	2456	<40	2145	610
FEB-2019	7377	798	1854	<40	1583	620
MAR-2019	7412	790	2085	<40	1752	610
APR-2019	7366	793	2141	<40	1746	610
MAY-2019	7427	792	2127	<40	1766	620
JUN-2019	7371	803	1926	<40	1594	616
JUL-2019	7381	811	2111	<40	1694	620
AUG-2019	7370	810	2105	<40	1619	600
SEP-2019	7349	806	2012	<40	1566	600
OCT-2019	7404	786	2140	<40	1741	620
NOV-2019	7351	781	2027	<40	1575	630
DEC-2019	7352	777	1700	<40	1279	610
JAN-2020	7368	775	2227	<40	1686	610
FEB-2020	7342	780	1883	<40	1368	628
MAR-2020	7398	770	1630	<40	1122	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	1459	3449	73	73	65	350
FEB-2019	1490	3368	75	108	66	590
MAR-2019	1458	3509	74	636	61	400
APR-2019	1496	3405	81	<50	71	480
MAY-2019	1443	3650	78	87	69	450
JUN-2019	1504	3422	79	<40	71	550
JUL-2019	1492	3497	71	<40	58	530
AUG-2019	1514	3442	82	<40	69	520
SEP-2019	1541	3320	95	<40	78	580
OCT-2019	1481	3625	81	102	69	470
NOV-2019	1501	3575	68	<40	57	560
DEC-2019	1486	3663	58	<40	48	480
JAN-2020	1460	3800	71	255	45	410
FEB-2020	1504	3646	72	<40	55	480
MAR-2020	1461	3827	53	<40	34	530

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	1459	14	20	191	159	35	13564
FEB-2019	7349	1490	7	16	160	181	-15	13593
MAR-2019	7371	1458	15	13	187	150	22	13613
APR-2019	7326	1496	10	15	152	181	-45	13641
MAY-2019	7390	1443	11	22	197	138	64	13684
JUN-2019	7331	1504	14	13	137	191	-59	13705
JUL-2019	7345	1492	13	13	181	164	14	13728
AUG-2019	7338	1514	12	18	170	177	-7	13764
SEP-2019	7314	1541	14	15	181	201	-24	13791
OCT-2019	7330	1481	3	13	222	148	16	13820
NOV-2019	7324	1501	9	17	164	169	-6	13853
DEC-2019	7322	1486	8	13	165	157	-2	13881
JAN-2020	7340	1460	9	12	181	155	18	13904
FEB-2020	7311	1504	11	19	141	174	-29	13940
MAR-2020	7372	1461	14	22	213	156	61	13975

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6803	486	53	7397	0.74%	91.97%	6.57%	0.72%	100.00%
FEB-2019	54	6782	492	49	7377	0.73%	91.93%	6.67%	0.66%	100.00%
MAR-2019	60	6812	490	50	7412	0.81%	91.91%	6.61%	0.67%	100.00%
APR-2019	57	6771	490	48	7366	0.77%	91.92%	6.65%	0.65%	100.00%
MAY-2019	55	6835	492	45	7427	0.74%	92.03%	6.62%	0.61%	100.00%
JUN-2019	57	6785	481	48	7371	0.77%	92.05%	6.53%	0.65%	100.00%
JUL-2019	61	6782	490	48	7381	0.83%	91.88%	6.64%	0.65%	100.00%
AUG-2019	61	6776	483	50	7370	0.83%	91.94%	6.55%	0.68%	100.00%
SEP-2019	57	6754	486	52	7349	0.78%	91.90%	6.61%	0.71%	100.00%
OCT-2019	60	6804	488	52	7404	0.81%	91.90%	6.59%	0.70%	100.00%
NOV-2019	59	6756	486	50	7351	0.80%	91.91%	6.61%	0.68%	100.00%
DEC-2019	61	6765	478	48	7352	0.83%	92.02%	6.50%	0.65%	100.00%
JAN-2020	60	6766	485	57	7368	0.81%	91.83%	6.58%	0.77%	100.00%
FEB-2020	59	6747	476	60	7342	0.80%	91.90%	6.48%	0.82%	100.00%
MAR-2020	61	6800	486	51	7398	0.82%	91.92%	6.57%	0.69%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3463 48%	12 41%	3262 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3308 46%
MAR-2019	6 30%	3474 48%	6 30%	3277 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3307 46%
APR-2019	12 43%	3473 48%	12 43%	3281 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3250 45%
MAY-2019	14 33%	3504 48%	14 33%	3312 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	24 57%	3264 45%
JUN-2019	3 14%	3484 49%	3 14%	3296 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	609 8%	16 76%	3205 45%
JUL-2019	8 36%	3508 49%	8 36%	3327 46%	0 0%	39 1%	0 0%	2 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3183 44%
AUG-2019	14 39%	3515 49%	12 33%	3340 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	631 9%	20 56%	3145 44%
SEP-2019	5 19%	3497 49%	5 19%	3321 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	656 9%	17 63%	3126 44%
OCT-2019	4 14%	3517 49%	2 7%	3335 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	671 9%	23 82%	3148 44%
NOV-2019	8 24%	3462 48%	7 21%	3285 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	730 10%	19 58%	3115 44%
DEC-2019	1 4%	3442 48%	1 4%	3264 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	14 50%	857 12%	13 46%	3053 43%
JAN-2020	2 9%	3408 47%	2 9%	3232 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 39%	1028 14%	12 52%	2964 41%
FEB-2020	3 8%	3360 47%	3 8%	3188 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	16 44%	1173 16%	17 47%	2828 40%
MAR-2020	4 11%	3328 46%	4 11%	3163 44%	1 3%	34 0%	0 0%	1 0%	0 0%	0 0%	20 57%	1330 18%	11 31%	2723 38%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3677	51%
MAR-2019	14	70%	3703	51%
APR-2019	16	57%	3666	51%
MAY-2019	28	67%	3693	51%
JUN-2019	18	86%	3651	51%
JUL-2019	14	64%	3656	51%
AUG-2019	22	61%	3628	51%
SEP-2019	22	81%	3630	51%
OCT-2019	24	86%	3672	51%
NOV-2019	25	76%	3675	51%
DEC-2019	27	96%	3717	52%
JAN-2020	21	91%	3768	52%
FEB-2020	33	92%	3788	53%
MAR-2020	30	86%	3863	54%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1070 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1487 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1478 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1480 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1003 39%	9 100%	1465 56%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	982 38%	6 100%	1484 57%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	969 38%	11 92%	1461 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	955 37%	12 92%	1484 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	959 37%	13 93%	1493 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	941 37%	3 100%	1472 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	924 37%	7 100%	1466 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	912 37%	6 86%	1466 59%	1 14%	97 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 11%	874 36%	8 89%	1456 60%	0 0%	97 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAR-2020	0 0%	2 0%	1 10%	861 36%	9 90%	1440 60%	0 0%	94 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	6 100%	648 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	636 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	635 35%	0 0%	211 12%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	207 11%	0 0%	647 36%	0 0%	326 18%
SEP-2019	0 0%	1 0%	4 80%	610 35%	0 0%	209 12%	0 0%	622 35%	1 20%	325 18%
OCT-2019	0 0%	1 0%	6 60%	613 35%	1 10%	211 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	614 37%	0 0%	209 12%	1 14%	525 31%	1 14%	326 19%
DEC-2019	0 0%	1 0%	3 100%	608 37%	0 0%	203 12%	0 0%	513 31%	0 0%	325 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 12%	0 0%	502 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	484 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	548 36%	0 0%	195 13%	0 0%	466 31%	0 0%	315 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2436 63%	5 23%	726 19%	0 0%	40 1%	1 5%	652 17%
MAR-2019	0 0%	27 1%	8 62%	2482 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2496 64%	3 21%	738 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2560 64%	6 21%	747 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2561 65%	3 23%	744 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	13 81%	2607 65%	3 19%	756 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2649 65%	1 4%	754 19%	0 0%	36 1%	3 11%	626 15%
SEP-2019	0 0%	28 1%	7 47%	2653 65%	6 40%	756 19%	0 0%	37 1%	2 13%	629 15%
OCT-2019	0 0%	28 1%	13 87%	2723 66%	1 7%	757 18%	0 0%	34 1%	1 7%	630 15%
NOV-2019	3 13%	88 2%	16 70%	2746 65%	4 17%	769 18%	0 0%	33 1%	0 0%	622 15%
DEC-2019	13 65%	231 5%	6 30%	2723 64%	1 5%	743 17%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	424 10%	7 39%	2693 62%	0 0%	706 16%	0 0%	32 1%	2 11%	595 14%
FEB-2020	14 52%	605 14%	11 41%	2651 60%	2 7%	653 15%	0 0%	29 1%	0 0%	577 13%
MAR-2020	19 70%	757 17%	6 22%	2625 58%	1 4%	622 14%	1 4%	30 1%	0 0%	561 12%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1833	24.78	1481	20.02	3061	41.38	100	1.35	53	0.72	869	11.75
FEB-2019	1804	24.45	1479	20.05	3076	41.70	99	1.34	49	0.66	870	11.79
MAR-2019	1794	24.20	1473	19.87	3126	42.17	98	1.32	50	0.67	871	11.75
APR-2019	1760	23.89	1461	19.83	3139	42.61	100	1.36	48	0.65	858	11.65
MAY-2019	1774	23.89	1450	19.52	3203	43.13	97	1.31	45	0.61	858	11.55
JUN-2019	1742	23.63	1441	19.55	3202	43.44	95	1.29	48	0.65	843	11.44
JUL-2019	1715	23.24	1429	19.36	3240	43.90	92	1.25	48	0.65	857	11.61
AUG-2019	1686	22.88	1403	19.04	3294	44.69	94	1.28	50	0.68	843	11.44
SEP-2019	1699	23.12	1364	18.56	3301	44.92	93	1.27	52	0.71	840	11.43
OCT-2019	1706	23.04	1344	18.15	3362	45.41	93	1.26	52	0.70	847	11.44
NOV-2019	1669	22.70	1274	17.33	3428	46.63	91	1.24	50	0.68	839	11.41
DEC-2019	1644	22.36	1250	17.00	3490	47.47	92	1.25	48	0.65	828	11.26
JAN-2020	1619	21.97	1208	16.40	3570	48.45	87	1.18	57	0.77	827	11.22
FEB-2020	1577	21.48	1153	15.70	3652	49.74	85	1.16	60	0.82	815	11.10
MAR-2020	1547	20.91	1136	15.36	3756	50.77	85	1.15	51	0.69	823	11.12

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	22	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	13	0	2	5	2	4	300
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	22	4	0	3	1	10	550

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12252	3830
FEB-2019	12260	3829
MAR-2019	12290	3859
APR-2019	12317	3883
MAY-2019	12333	3884
JUN-2019	12333	3889
JUL-2019	12350	3904
AUG-2019	12382	3921
SEP-2019	12401	3939
OCT-2019	12435	3963
NOV-2019	12457	3972
DEC-2019	12481	3986
JAN-2020	12544	4039
FEB-2020	12589	4069
MAR-2020	12595	4065

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
March 2020

N = 7398

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2020

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	7	7	*
	35-49	9	10	*
	50+	27	39	*
	Total HSDA:	43	56	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	98	55	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	364	495	282	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	52
	50+	*	*	82
Total HSDA:	195	268	148	
Total HA:		676	917	513

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	59	60	*
	35-49	180	201	*
	50+	432	651	*
Total HA:		676	917	513

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	540	732	415
Female	136	185	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	513	55	600	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	19	11
	5 years or more	11	7
	<5 years	13	10
	Total HSDA:	43	28
KOOTENAY BOUNDARY	10 years or more	46	33
	5 years or more	15	11
	<5 years	13	11
	Total HSDA:	74	55
OKANAGAN	10 years or more	227	165
	5 years or more	72	61
	<5 years	65	56
	Total HSDA:	364	282
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	109	81
	5 years or more	46	39
	<5 years	40	28
	Total HSDA:	195	148
Total HA:		676	513

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	401	290
5 years or more	144	118
<5 years	131	105
Total HA:	676	513

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	16	26
KOOTENAY BOUNDARY	76	124	27	47
OKANAGAN	226	929	60	285
THOMPSON/CARIBOO/SHUSWAP	138	517	38	141
Total:	486	1634	141	499

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	94

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	25
	35-49	98	108	73
	50+	240	315	189
	Total HSDA:	377	464	293
FRASER NORTH	0-19	7	7	*
	20-34	116	116	*
	35-49	345	373	*
	50+	574	903	*
	Total HSDA:	1042	1399	790
FRASER SOUTH	0-19	6	6	5
	20-34	112	114	85
	35-49	329	375	266
	50+	553	814	445
	Total HSDA:	1000	1309	801
Total HA:		2419	3172	1884

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	19	19	13
	20-34	261	265	187
	35-49	772	856	602
	50+	1367	2032	1082
Total HA:		2419	3172	1884

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1835	2430	1441
Female	584	742	443

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1884	52	630	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	226	177
	5 years or more	72	56
	<5 years	79	60
	Total HSDA:	377	293
FRASER NORTH	10 years or more	587	424
	5 years or more	249	195
	<5 years	206	171
	Total HSDA:	1042	790
FRASER SOUTH	10 years or more	567	447
	5 years or more	223	169
	<5 years	210	185
	Total HSDA:	1000	801
Total HA:		2419	1884

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1380	1048
	5 years or more	544	420
	<5 years	495	416
Total HA:		2419	1884

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	145	494	29	49
FRASER NORTH	256	1579	49	233
FRASER SOUTH	223	1492	49	460
Total:	624	3565	127	742

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	203
FRASER NORTH	649
FRASER SOUTH	493
Total:	1345

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		345	495
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		176	225
VANCOUVER	0-19	23	23	7
	20-34	450	465	312
	35-49	1371	1543	972
	50+	2841	4866	2066
	Total HSDA:		4685	6897
Total HA:		5206	7617	3788

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	27	27	9
	20-34	507	523	359
	35-49	1495	1679	1070
	50+	3177	5388	2350
Total HA:		5206	7617	3788

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4602	6694	3342
Female	602	921	446

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3788	53	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	190	156
	5 years or more	90	77
	<5 years	65	62
	Total HSDA:	345	295
RICHMOND	10 years or more	101	72
	5 years or more	37	30
	<5 years	38	34
	Total HSDA:	176	136
VANCOUVER	10 years or more	2828	1933
	5 years or more	1107	804
	<5 years	750	620
	Total HSDA:	4685	3357
Total HA:		5206	3788

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3119	2161
	5 years or more	1234	911
	<5 years	853	716
Total HA:		5206	3788

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	183	501	60	172
RICHMOND	44	289	12	93
VANCOUVER	642	10934	219	5255
Total:	869	11724	291	5520

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	120

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		335	470
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		127	169
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	57
	35-49	*	*	148
	50+	*	*	370
	Total HSDA:		751	1059
Total HA:		1213	1698	958

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1213	1698	958

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1004	1402	801
Female	209	296	157

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	958	54	570	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	183	151
	5 years or more	76	62
	<5 years	76	63
	Total HSDA:	335	276
NORTH VANCOUVER ISLAND	10 years or more	72	61
	5 years or more	35	29
	<5 years	20	17
	Total HSDA:	127	107
SOUTH VANCOUVER ISLAND	10 years or more	437	308
	5 years or more	160	139
	<5 years	154	128
	Total HSDA:	751	575
Total HA:		1213	958

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	692	520
5 years or more	271	230
<5 years	250	208
Total HA:	1213	958

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	204	872	82	201
NORTH VANCOUVER ISLAND	151	268	50	79
SOUTH VANCOUVER ISLAND	219	1809	46	572
Total:	574	2949	178	852

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	52
NORTH VANCOUVER ISLAND	40
SOUTH VANCOUVER ISLAND	111
Total:	203

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	20-34	11	12	8
	35-49	16	32	14
	50+	41	64	34
	Total HSDA:	68	108	56
NORTHERN INTERIOR	0-19	5	5	*
	20-34	23	24	*
	35-49	71	90	*
	50+	90	153	*
	Total HSDA:	189	272	144
Total HA:		297	428	223

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	36	38	*
	35-49	106	144	*
	50+	149	240	*
Total HA:		297	428	223

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	179	263	135
Female	118	165	88

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	223	50	540	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	13	*
	<5 years	6	*
	Total HSDA:	40	23
NORTH WEST	10 years or more	34	26
	5 years or more	22	19
	<5 years	12	11
	Total HSDA:	68	56
NORTHERN INTERIOR	10 years or more	78	57
	5 years or more	61	52
	<5 years	50	35
	Total HSDA:	189	144
Total HA:		297	223

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	133	94
	5 years or more	96	80
	<5 years	68	49
Total HA:		297	223

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	43	64	8	9
NORTH WEST	82	164	18	34
NORTHERN INTERIOR	117	471	20	188
Total:	242	699	46	231

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	12
Total:	38

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	23	39	*
	THOMPSON/CARIBOO/SHUSWAP	26	47	*
	Total HA:	61	105	44
FRASER	FRASER EAST	38	48	31
	FRASER NORTH	54	90	45
	FRASER SOUTH	78	111	54
	Total HA:	170	249	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	8	13	6
	VANCOUVER	483	859	382
	Total HA:	516	920	412
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	52	81	43
	NORTH VANCOUVER ISLAND	19	28	17
	SOUTH VANCOUVER ISLAND	40	84	34
	Total HA:	111	193	94
NORTHERN	NORTH EAST	11	13	8
	NORTH WEST	26	57	24
	NORTHERN INTERIOR	72	111	61
	Total HA:	109	181	93
Total:		967	1648	773

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	608	1052	487
Female	359	596	286

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	773	52	480	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

